1.原文连结(必须检附)：
http://www.analystratings.com/2016/02/23/maxim-group-maintains-a-buy-rating-on-stellar-biotechnologies-2/432156/
2.原文内容：
(截取部份重点及翻译)
美心集团 对Stellar Biotechnologie 维持买入评等 目标价17美元
Maxim Group Maintains a Buy Rating on Stellar Biotechnologies
By George Macdonald
In a report released yesterday, Jason McCarthy from Maxim Group maintained a
Buy rating on Stellar Biotechnologies (NASDAQ: SBOT), with a price target of
$17. The company’s shares closed yesterday at $5.84. ( 目标价17美元 个人评:
该股因美生技股回跌至5.84)
Mccarthy noted, “OBI Pharma (TAIPEI – 4174:TT – $552.00- NR), a consumer
of Stellar’s KLH, announced that the company’s KLH-based immune therapy
OBI-822/821 showed in a post-hoc analysis that a sub-group of patients
(that mounted immune responses) had a highly significant improvement in PFS
and overall survival (OS) is trending towards statistical significance.
The full data has not been released yet.”
麦卡锡说，台湾浩鼎生技是Stellar Biotechnologies KLH 的购买者，该公司旗下以
KLH 为载体蛋白的免疫疗法
OBI822/821 显示在事后比较检定（Post hoc tests) 参与试验的病人若能产生免疫抗体
反应的次族群病患在 无疾病恶化存活期 PFS(progression free survival)有高度显著
意义的改善 总体存活率(OS)方面也呈现明显的正面趋势。完整的数据尚未发布。
Stellar Biotechnologies has an analyst consensus of Moderate Buy.
分析师的共识。恒星生技 适度买进
3.心得/评论(必需填写)：
世人皆醉我独醒? 难道只有我相信,虽然解盲没有过关,
只要浩鼎参加美国ASCO年会,公布DATA后,仍有很大的机会直接跟美国FDA申请药证?